Dr. Chowdhury has served as CEO and Chairman of the Board of Nemaura Medical Inc. since 2013. He has over 20 years of experience in the Pharmaceutical and Medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents across 15 technology platforms within the medical device and pharmaceutical sectors and has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier. Dr. Chowdhury is a regular speaker at international conferences in this field and serves on the Board of Medilink East Midlands, UK. He holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and a Doctorate from the University of Oxford on nano-medicine and drug delivery.
Dr. Faz Chowdhury trained as a pharmaceutical scientist, and holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-drug delivery. He has over 18 years experience in product development, manufacturing, and technical and corporate management.
Mr. Mclarney brings a wealth of experience within International Finance, Accounting, and Process Development & Control having been a Chartered Accountant since 1999. He has a strong track record of driving profitable growth across businesses encompassing ecommerce, retail, logistics, and supply chain operations at an international level. Mr. McIarney has held various Senior Finance & Operational roles, including most recently the position of Senior Director, International Finance at Lands’ End Inc. from January 2016 to May 2020 where he was responsible for the Finance and Operations teams across the European and Japanese business units. From February 2007 to September 2015, Mr. Mclarney worked for Office Depot in a range of increasingly senior roles culminating in the position of Senior Director of Finance for the largest business unit within the European group; during his time at Office Depot, Mr. Mclarney was also directly involved in the development and delivery of new service offerings into existing markets in addition to the acquisition integration of new geographical markets, ranging in size and scale from Sweden to India and China. Prior to this, he spent over 10 years in practice, the majority of which was with Ernst & Young LLP. Before his transition into Accountancy, Mr. McIarney studied Law and obtained his Legal Practice Certificate.
Professor Karrar Khan has over 35 years of experience in drug discovery, pharmaceutical development, and registration and managing pharmaceutical scientists. His experience includes 20 years of combined experience as Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll and two years as Director for OSI, where he managed its pharmaceutical development, analytical operations, and DMPK. His expertise includes clinical development across the Phase 1 to Phase 4 spectrum and launching over 60 bringing prescription and OTC products on a global level. He is a Qualified person under the EC quality assurance directive.
Professor Khan has over 35 years’ experience of drug discovery, pharmaceutical development, registration and managing pharmaceutical scientists. His experience includes 20 years as Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll and two years as Director for OSI where he managed their pharmaceutical development, analytical operations and DMPK.
Dr. Schaebsdau has over 15 years of executive level experience in the CGM, Blood Glucose Monitoring (BGM), and insulin delivery industries. He began his career in 2004 with Abbott Diabetes Care, where he was a member of the M&A and post-merger integration teams responsible for the acquisition of TheraSense and its FreeStyle Navigator CGM. From September 2016 until January 2019, he was the General Manager of Dexcom Germany, which under his leadership became the fastest growing organization in Dexcom’s history, achieving triple-digit revenue and new patient growth every year. Under Dr. Schaebsdau’s leadership at Abbott, two generations of CGM, G5 and G6, were successfully launched and negotiations with public insurers completed, which resulted in full reimbursement for >85% of the German population. From 2009 until August 2015, at Roche Diabetes Care, he was Senior Vice-President, Head of Global Strategy and Business Development, completing several strategic acquisitions, partnerships, and licensing deals. In September 2015, he founded his own firm as an exclusive distributor in Europe, the Middle East, and Africa for UniStrip®, the world’s first generic blood glucose test strip. Since September 2015, he has been a member of the Advisory Board of Peppermint Venture Partners. Dr. Schaebsdau studied Medicine at the University of Giessen and completed residencies in urology and surgery at the University of Chicago, University of Hannover, and University of Freiburg. He is licensed to practice medicine in the U.S. and Germany. During his residency at the University of Hannover, he conducted primary research in neurophysiology with a grant from the DFG (Deutsche Forschungsgemeinschaft) and completed his Ph.D. In 1993, he received an MBA from The Wharton School of the University of Pennsylvania.
Dr. Schaebsdau has over 15 years of executive level experience in the CGM, Blood Glucose Monitoring (BGM) and insulin delivery industries, which started in 2004 during his tenure with Abbott Diabetes Care, where he was a member of the M&A and post-merger integration teams responsible for the acquisition of TheraSense and its FreeStyle Navigator CGM. From September 2016 until January 2019, he was the General Manager of Dexcom Germany, which during his leadership became the fastest growing organization in
David Scott is a trained chemist with over 35 years of experience in the Pharmaceutical Industry, spanning deal brokering, marketing, strategic planning, finance, business development, and acquisitions. He is a skilled negotiator who has closed a number of major deals for inward and outward licensing of pharmaceutical products, delivery systems, and technologies. He has also provided licensing training for a number of multinational pharma companies and training organizations and has published widely (he is the author of the best-selling report, “Scrip’s Practical Guide to Pharmaceutical Licensing”). David is also an accredited “Certified Licensing Professional”.
David Scott is a trained chemist with over 35 years’ experience in the Pharmaceutical Industry spanning deal brokering, marketing, strategic planning, finance, business development and acquisitions. He is a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies.
Mr. Johnson was elected as a director in July 2017. He is currently serving in executive positions in Diagnostax,, EQIQ, and Protech Professional. Mr. Johnson received his first class Masters of Science in Mathematics and Physics from the University of Manchester, UK.
Dr. Natha was elected as a director in July 2017. He is currently practicing as an eye surgeon in the UK National Health Service (NHS) and is the clinical lead for a retinopathy screening program for over 20,000 patients with diabetes in the Ashton, Wigan, and Leigh region. He has published several articles in the medical literature and is a peer reviewer for the English National Diabetic Retinopathy Screening Programme. Dr. Natha graduated with honors from the University of Liverpool Medical School.
Mr. Moore was elected as a director in August 2017. He is currently working as a management consultant, having built up three decades of experience in the accountancy and consultancy fields at leading accountancy firms, including Grant Thornton, KPMG, and PricewaterhouseCoopers. He is a practicing Chartered Tax Adviser and earned his first class Bachelor of Arts in French and Russian from the University of Northumbria, UK.
Dr. Chowdhury has served as CEO and Chairman of the Board of Nemaura Medical Inc., since 2013. He has over 20 years of experience in the Pharmaceutical and Medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents across 15 technology platforms within the medical device and pharmaceutical sectors and has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier. Dr. Chowdhury is a regular speaker at international conferences in this field and serves on the Board of Medilink East Midlands, UK. He holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and a Doctorate from the University of Oxford on nano-medicine and drug delivery.
Mr. Timol has served as member of the board of Nemaura Medical since its formation in December 2013. He has co-founded, managed, and funded several biotech and life science companies and led the investment consortium that provided capital for the first two funding rounds for Nemaura Medical. Mr. Timol obtained his Bachelor of Arts degree in Economics from the University of Central Lancashire, UK.
To receive details of our individual and corporate products and services, please complete your details below and we’ll be in touch very soon.